The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
PEG-uricase in the management of treatment-resistant gout and hyperuricemia
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RASMOL: biomolecular graphics for all
Sayle, R. (1995) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)89080-5 · Cited by 2,575
A Role for Uric Acid in the Progression of Renal Disease
Kang, D.-H., Nakagawa, T., Feng, L., Watanabe, S., Han, L., Mazzali, M., Truong, L., Harris, R., & Johnson, R. J. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000034910.58454.fd · Cited by 1,304
Hande, K. R., Noone, R. M., & Stone, W. J. (1984) · The American Journal of Medicine · doi:10.1016/0002-9343(84)90743-5 · Cited by 680
Poly(ethylene glycol): Chemistry and Biological Applications
(1997) · ACS Symposium Series · doi:10.1021/bk-1997-0680 · Cited by 646
Two independent mutational events in the loss of urate oxidase during hominoid evolution
Wu, X., Muzny, D. M., Chi Lee, C., & Thomas Caskey, C. (1992) · Journal of Molecular Evolution · doi:10.1007/bf00163854 · Cited by 535
Effect of urate‐lowering therapy on the velocity of size reduction of tophi in chronic gout
Perez‐Ruiz, F., Calabozo, M., Pijoan, J. I., Herrero‐Beites, A. M., & Ruibal, A. (2002) · Arthritis Care & Research · doi:10.1002/art.10511 · Cited by 454
Self-citationGout and the risk of acute myocardial infarction
Krishnan, E., Baker, J. F., Furst, D. E., & Schumacher, H. R. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22014 · Cited by 430
Wallace, K. L., Riedel, A. A., Joseph‐Ridge, N., & Wortmann, R. L. (2004) · PubMed · Cited by 426
Ganson, N. J., Kelly, S. J., Scarlett, E., Sundy, J. S., & Hershfield, M. S. (2005) · Arthritis Research & Therapy · doi:10.1186/ar1861 · Cited by 350
A concise history of gout and hyperuricemia and their treatment.
Nuki, G., & Simkin, P. A. (2006) · Arthritis Research & Therapy · doi:10.1186/ar1906 · Cited by 331
Hainsworth, J. D., Litchy, S., Shaffer, D. W., Lackey, V. L., Grimaldi, M., & Greco, F. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.191 · Cited by 330
Metabolic studies of allopurinol, an inhibitor of xanthine oxidase
Elion, G. B., Kovensky, A., Hitchings, G. H., Metz, E., & Rundles, R. W. (1966) · Biochemical Pharmacology · doi:10.1016/0006-2952(66)90163-8 · Cited by 327
Hyperuricemia and Incidence of Hypertension Among Men Without Metabolic Syndrome
Krishnan, E., Kwoh, C. K., Schumacher, H. R., & Kuller, L. (2007) · Hypertension · doi:10.1161/01.hyp.0000254480.64564.b6 · Cited by 293
Hyperuricemia and urate nephropathy in urate oxidase-deficient mice.
Wu, X., Wakamiya, M., Vaishnav, S., Geske, R., Montgomery, C., Jones, P., Bradley, A., & Caskey, C. T. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.2.742 · Cited by 291
Essential Hypertension, Progressive Renal Disease, and Uric Acid: A Pathogenetic Link?
Johnson, R. J., Segal, M. S., Srinivas, T., Ejaz, A., Mu, W., Roncal, C., Sánchez-Lozada, L. G., Gersch, M., Rodriguez-Iturbe, B., Kang, D.-H., et al. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005010063 · Cited by 280
A literature review of the epidemiology and treatment of acute gout
Kim, K. Y., Ralph Schumacher, H., Hunsche, E., Wertheimer, A. I., & Kong, S. X. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80158-3 · Cited by 274
Johnson, R. J., Kivlighn, S. D., Kim, Y.-G., Suga, S., & Fogo, A. B. (1999) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(99)70295-7 · Cited by 267
Becker, M. A., Schumacher, H. R., Wortmann, R. L., MacDonald, P. A., Palo, W. A., Eustace, D., Vernillet, L., & Joseph‐Ridge, N. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20935 · Cited by 266
Prasad, A., & Oberleas, D. (1974) · The Lancet · doi:10.1016/s0140-6736(74)92430-1 · Cited by 225
Sundy, J. S., Ganson, N. J., Kelly, S. J., Scarlett, E. L., Rehrig, C. D., Huang, W., & Hershfield, M. S. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22403 · Cited by 221
Management of Acute and Chronic Gouty Arthritis: Present State-of-the-Art
Schlesinger, N. (2004) · Drugs · doi:10.2165/00003495-200464210-00003 · Cited by 220
Veronese, F. M., Largajolli, R., Boccú, E., Benassi, C. A., & Schiavon, O. (1985) · Applied Biochemistry and Biotechnology · doi:10.1007/bf02798546 · Cited by 187
Serum Urate Levels and Gout Flares: Analysis From Managed Care Data
Sarawate, C. A., Patel, P. A., Schumacher, H. R., Yang, W., Brewer, K. K., & Bakst, A. W. (2006) · JCR: Journal of Clinical Rheumatology · doi:10.1097/01.rhu.0000209882.50228.9f · Cited by 186
Jeha, S., Kantarjian, H., Irwin, D., Shen, V, Shenoy, S., Blaney, S., Camitta, B., & Pui, C.-H. (2005) · Leukemia · doi:10.1038/sj.leu.2403566 · Cited by 181
Gout: On the brink of novel therapeutic options for an ancient disease
Bieber, J. D., & Terkeltaub, R. A. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20438 · Cited by 181
Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies
Pui, C.-H., Relling, M., Lascombes, F., Harrison, P., Struxiano, A., Mondesir, J.-M., Ribeiro, R., Sandlund, J., Rivera, G., Evans, W., et al. (1997) · Leukemia · doi:10.1038/sj.leu.2400850 · Cited by 174
Crystal Structure of the protein drug urate oxidase-inhibitor complex at 2.05 Å resolution
Colloc'h, N., Hajji, M. E., Bachet, B., L'Hermite, G., Schiltz, M., Prangé, T., Castro, B., & Mornon, J.-P. (1997) · Nature Structural & Molecular Biology · doi:10.1038/nsb1197-947 · Cited by 164
Effects of a xanthine oxidase inhibitor on thiopurine metabolism, hyperuricemia and gout
(2001) · CRC Press eBooks · doi:10.3109/9780203214237-143 · Cited by 158
Veronese, F. M., Caliceti, P., & Schiavon, O. (1997) · Journal of Bioactive and Compatible Polymers · doi:10.1177/088391159701200303 · Cited by 128
Hewer, A. J. H., & Keele, C. A. (1947) · The Lancet · doi:10.1016/s0140-6736(47)92042-4 · Cited by 114
Lee, L. S., Conover, C., Shi, C., et al. (1999) · Bioconjugate Chemistry · doi:10.1021/bc990076o · Cited by 113
Bomalaski, J. S., Holtsberg, F. W., Ensor, M., & Clark, M. A. (2002) · PubMed · Cited by 98
Hemolysis and Methemoglobinemia Secondary to Rasburicase Administration
Browning, L. A., & Kruse, J. A. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1g272 · Cited by 95
Immunological Properties of Uricase Conjugated to Neutral Soluble Polymers
Caliceti, P., Schiavon, O., & Veronese, F. M. (2001) · Bioconjugate Chemistry · doi:10.1021/bc000119x · Cited by 90
Bomalaski, J. S., & Clark, M. A. (2004) · Current Rheumatology Reports · doi:10.1007/s11926-004-0075-3 · Cited by 78
Kelly, S. J., Delnomdedieu, M., Oliverio, M. I., WILLIAMS, D. L., Saifer, M. G. P., Sherman, M. R., Coffman, T. M., Johnson, G. A., & Hershfield, M. S. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1251001 · Cited by 78
Self-citationEmerging therapies in the long‐term management of hyperuricaemia and gout
Stamp, L. K., O'Donnell, J. L., & Chapman, P. T. (2007) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2007.01315.x · Cited by 69
On-line characterization of polyethylene glycol-modified proteins
Kunitani, M. G., Dollinger, G. D., Johnson, D., & Kresin, L. (1991) · Journal of Chromatography A · doi:10.1016/0021-9673(91)85014-7 · Cited by 56
Chua, C. C., Greenberg, M. L., Viau, A. T., Nucci, M., Brenckman, W. D., & Hershfleld, M. S. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-109-2-114 · Cited by 54
Rasburicase treatment in severe tophaceous gout: a novel therapeutic option
Moolenburgh, J. D., Reinders, M. K., & Jansen, T. (2005) · Clinical Rheumatology · doi:10.1007/s10067-005-0043-y · Cited by 52
FATAL STEVENS-JOHNSON SYNDROME IN A PATIENT ON CAPTOPRIL AND ALLOPURINOL
Pennell, D. J., NUNAN, T. O., O'Doherty, M. J., & Croft, D. N. (1984) · The Lancet · doi:10.1016/s0140-6736(84)91807-5 · Cited by 47
Uricase and other novel agents for the management of patients with treatment-failure gout
Sundy, J. S., & Hershfield, M. S. (2007) · Current Rheumatology Reports · doi:10.1007/s11926-007-0041-y · Cited by 47
Studies on antigenicity of the polyethylene glycol (PEG)-modified uricase
Tsuji, J., Hirose, K., Kasahara, E., Naitoh, M., & Yamamoto, I. (1985) · International Journal of Immunopharmacology · doi:10.1016/0192-0561(85)90158-4 · Cited by 44
Tumor lysis syndrome: pathophysiology, definition, and alternative treatment approaches.
Del Toro, G., Morris, E., & Cairo, M. (2005) · PubMed · Cited by 44
Uricolytic Activity of Purified Uricase in Two Human Beings
London, M., & Hudson, P. B. (1957) · Science · doi:10.1126/science.125.3254.937 · Cited by 40
New developments in clinically relevant mechanisms and treatment of hyperuricemia
Lee, S. H., & Terkeltaub, R. A. (2006) · Current Rheumatology Reports · doi:10.1007/s11926-996-0029-z · Cited by 25
Cited by
The Impact of PEGylation on Biological Therapies
Veronese, F. M., & Mero, A. (2008) · BioDrugs · doi:10.2165/00063030-200822050-00004 · Cited by 1,034
Turecek, P. L., Bossard, M. J., Schoetens, F., & Ivens, I. A. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.11.015 · Cited by 733
State of the art in PEGylation: The great versatility achieved after forty years of research
Pasut, G., & Veronese, F. M. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.10.037 · Cited by 720
Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation
Zhang, P., Sun, F., Liu, S., & Jiang, S. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.040 · Cited by 688
A Broader View: Microbial Enzymes and Their Relevance in Industries, Medicine, and Beyond
Gurung, N., Ray, S., Bose, S., & Rai, V. (2013) · BioMed Research International · doi:10.1155/2013/329121 · Cited by 687
Metadata
- Authors
- Sherman, M. R., Saifer, M. G. P., & Perez-Ruiz, F.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2008-01
- Volume
- 60
- Issue
- 1
- Pages
- 59-68
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2027026258
- Cited by
- 291
- References
- 46
- FWCI
- 1.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.